Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Share-based Compensation: 2017-2025

Historic Share-based Compensation for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $3.2 million.

  • Cidara Therapeutics' Share-based Compensation rose 322.24% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 209.35%. This contributed to the annual value of $3.9 million for FY2024, which is 27.64% up from last year.
  • Latest data reveals that Cidara Therapeutics reported Share-based Compensation of $3.2 million as of Q3 2025, which was up 7.31% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Share-based Compensation ranged from a high of $3.2 million in Q3 2025 and a low of $640,000 during Q1 2023.
  • For the 3-year period, Cidara Therapeutics' Share-based Compensation averaged around $1.3 million, with its median value being $796,000 (2023).
  • Per our database at Business Quant, Cidara Therapeutics' Share-based Compensation crashed by 52.17% in 2023 and then soared by 322.24% in 2025.
  • Cidara Therapeutics' Share-based Compensation (Quarterly) stood at $1.4 million in 2021, then crashed by 50.62% to $673,000 in 2022, then grew by 23.33% to $830,000 in 2023, then spiked by 99.76% to $1.7 million in 2024, then soared by 322.24% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $3.0 million for Q2 2025, and $1.7 million during Q1 2025.